Trade Names:Dobutamine Hydrochloride- Injection 12.5 mg/mL
Stimulates beta 1 receptors in heart, causing more complete and forceful contractions (inotropy) without significantly increasing heart rate or BP.
Methylation and conjugation.
Half-life is 2 min. Urinary excretion of metabolites.
1 to 2 min.
Up to 10 min.
Treatment of cardiac decompensation caused by organic heart disease or cardiac surgical procedures.
Congenital heart disease in children undergoing diagnostic cardiac catheterization.
Idiopathic hypertrophic subaortic stenosis; hypersensitivity to any component of the product.
IV infusion 2.5 to 15 mcg/kg/min; titrate to desired response; increase in heart rate more than 10% may develop in rate greater than 20 mcg/kg/min; rates up to 40 mcg/kg/min are rarely used. Duration of therapy up to 72 h without decrease in clinical effectiveness may be used.
Store at 59° to 86°F. Avoid excessive heat. Protect from freezing. For pharmacy bulk packages, discard any unused portion within 4 h after initial closure entry. Use IV solutions within 24 h after dilution.
May antagonize beta receptor–stimulating activity of dobutamine.Furazolidone, methyldopa, nitroprusside, rauwolfia alkaloids
Hypertension may result.Guanethidine
May increase pressor response.Halogenated hydrocarbon anesthetics
May increase risk of arrhythmias by sensitizing cardiac tissue to sympathomimetic agents.Tricyclic antidepressants
May potentiate effect of dobutamine; use combination with caution.
Chemically incompatible with sodium bicarbonate or other alkaline solutions.
None well documented.
Increased premature ventricular beats (5%); anginal pain, nonspecific chest pain, palpitations (1% to 3%); decreased BP; exaggerated chronotropic and pressor effects; increased BP; increased heart rate; increased ventricular ectopic activity.
Headache (1% to 3%).
Nausea (1% to 3%).
Inflammation after inadvertent infiltration; phlebitis.
Shortness of breath (1% to 3%).
Monitor vital signs, ECG, cardiac output, pulmonary capillary wedge pressure, central venous pressure, and urinary output carefully throughout infusion. Monitor patency and placement of IV catheter to reduce risk of extravasation and phlebitis. Consider monitoring serum potassium.
Category B .
Safety and efficacy not established.
Reactions suggestive of hypersensitivity, including skin rash, fever, eosinophilia, and bronchospasm, have been reported.
Use with extreme caution after myocardial ischemia. Avoid use in uncorrected hypovolemic states unless used as temporary emergency measure to maintain coronary and cerebral flow.
Use caution in sulfite-sensitive patients; some preparations contain sodium bisulfite.
May greatly increase BP and heart rate, especially with preexisting hypertension. Dose reduction may reverse effects. May precipitate or exacerbate ventricular ectopic activity.
Mild reduction in serum potassium, rarely to hyperkalemic levels, may occur.
Mild hypokalemia may occur.
Anginal and nonspecific chest pain, anorexia, anxiety, headache, hypertension, hypotension, MI, nausea, palpitations, shortness of breath, tachyarrhythmias, tremor, ventricular fibrillation, vomiting.
Copyright © 2009 Wolters Kluwer Health.